Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective

Neuro-Oncology

Volumn 10, Issue 6, 2008, Pages 1040-1060

  De Bont, Judith M ^a   Packer, Roger J ^b   Michiels, Erna M ^a   Den Boer, Monique L ^a   Pieters, Rob ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Biological characteristics; Ependymoma; Epigenetic events; Gene expression; Medulloblastoma; Protein expression; Signaling pathways

Indexed keywords

MYC PROTEIN; NOTCH RECEPTOR; PROTEIN P53; PROTEIN TYROSINE KINASE; SOMATOMEDIN; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

BRAIN DEVELOPMENT; BRAIN TUMOR; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CEREBELLUM VERMIS; CHILD DEATH; CHROMOSOME 17; CHROMOSOME 22; CHROMOSOME 7; CYTOGENETICS; DEREGULATION; DIAGNOSTIC ACCURACY; EPENDYMOMA; EPIGENETICS; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC IDENTIFICATION; HEMISPHERE; HUMAN; MEDULLOBLASTOMA; NEUROSURGERY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PEDIATRICS; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; CHILD; GENETICS;

BRAIN NEOPLASMS; CHILD; EPENDYMOMA; HUMANS; MEDULLOBLASTOMA;

EID: 60549111837     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-059     Document Type: Review

References (246)

1. Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-Oncology. 2002;4(4):278-299.
2. Ray A, Ho M, Ma J, et al. A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res. 2004;10(22):7613-7620.
3. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24(25):4202-4208.
4. Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmeta-static medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol. 2003;21(8):1581-1591.
5. Ris MD, Packer R, Goldwein J, et al. Intellectual ou tcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol. 2001;19(15):3470-3476.
6. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352(10):978-986.
7. Packer RJ, Biegel JA, Blaney S, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol. 2002;24(5):337-342.
8. Cowan R, Hoban P, Kelsey A, et al. The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medullo-blastoma. Br J Cancer. 1997;76(2):141-145.
9. Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by sonic hedgehog. Neuron. 1999;22(1):103-114.
10. Leung C, Lingbeek M, Shakhova O, et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature. 2004;428(6980):337-341.
11. Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell. 2004;6(3):229-240.
12. Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res. 2001;61(2):513-516.
13. Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14(15):1837-1851.
14. Novak A, Dedhar S. Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci. 1999;56(5-6):523-537.
15. Clifford SC, Lusher ME, Lindsey JC, et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular subgroup of medulloblastomas associated with a favorable prognosis. Cell Cycle. 2006;5(22):2666-2670.
16. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24(12):1924-1931.
17. Baeza N, Masuoka J, Kleihues P, et al. AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene. 2003;22(4):632-636.
18. Pizem J, Cort A, Zadravec-Zaletel L, et al. Survivin is a negative prognostic marker in medulloblastoma. Neuropathol Appl Neurobiol. 2005;31(4):422-428.
19. Fangusaro JR, Jiang Y, Holloway MP, et al. Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer. 2005;92(2):359-365.
20. Zorn AM, Barish GD, Williams BO, et al. Regulation of Wnt signaling by Sox proteins: XSox17 alpha/beta and XSox3 physically interact with beta-catenin. Mol Cell. 1999;4(4):487-498.
21. Lee CJ, Appleby VJ, Orme AT, et al. Differential expression of SOX4 and SOX11 in medulloblastoma. J Neurooncol. 2002;57(3):201-214.
22. de Bont JM, Kros JM, Passier MMCJ, et al. Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. Neuro-oncology. 2008 Jun 24 [epub ahead of print].
23. Neben K, Korshunov A, Benner A, et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res. 2004;64(9):3103-3111.
24. Dakubo GD, Mazerolle CJ, Wallace VA. Expression of Notch and Wnt pathway components an d activation of N otch sign aling in medulloblastomas from heterozygous patched mice. J Neurooncol. 2006;79(3):221-227.
25. Fan X, Mikolaen ko I, Elhassan I, et al. N otch1 and N otch2 h ave opposite effects on embryonal brain tumor growth. Cancer Res. 2004;64(21):7787-7793.
26. Baron M. An overview of the Notch signalling pathway. Semin Cell Dev Biol. 2003;14(2):113-119.
27. Adesina AM, Nguyen Y, Mehta V, et al. FOXG1 dysregulation is a frequent event in medulloblastoma. J Neurooncol. 2007;85(2):111-122.
28. Hallahan AR, Pritchard JI, Hansen S, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 2004;64(21):7794-7800.
29. Gilbertson RJ, Clifford SC, MacMeekin W, et al. Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res. 1998;58(17):3932-3941.
30. Ferretti E, Di Marcotu llio L, Gessi M, et al. Alternative splicing of the ErbB-4 cytoplasmic domain and its regulation by hedgeh og signaling identify distinct medulloblastoma subsets. Oncogene. 2006;25(55):7267-7273.
31. Elenius K, Choi CJ, Paul S, et al. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene. 1999;18(16):2607-2615.
32. Bal MM, Das Radotra B, Srinivasan R, et al. Expression of c-erbB-4 in medulloblastoma and its correlation with prognosis. Histopathology. 2006;49(1):92-93.
33. Hernan R, Fasheh R, Calabrese C, et al. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res. 2003;63(1):140-148.
34. Amin DN, Tuck D, Stern DF. Neuregulin-regulated gene expression in mammary carcinoma cells. Exp Cell Res. 2005;309(1):12-23.
35. Henriksson M, Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res. 1996;68:109-182.
36. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509-1512.
37. Rao G, Pedone CA, Coffin CM, et al. c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. Neoplasia. 2003;5(3):198-204.
38. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415(6870):436-442.
39. Browd SR, Kenney AM, Gottfried ON, et al. N-myc can substitute for insulin-like growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma. Cancer Res. 2006;66(5):2666-2672.
40. Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-Myc, n-Myc, TrkC, and anaplasia. J Neuropathol Exp Neurol. 2004;63(5):441-449.
41. Kenney AM, Widlund HR, Rowitch DH. Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development. 2004;131(1):217-228.
42. Zumkeller W, Westphal M. The IGF/IGFBP system in CNS malignancy. Mol Pathol. 2001;54(4):227-229.
43. Wang JY, Del Valle L, Gordon J, et al. Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas. Oncogene. 2001;20(29):3857-3868.
44. Urbanska K, Trojanek J, Del Valle L, et al. Inhibition of IGF-1 receptor in anchorage-independence attenuates GSK-3beta constitutive phos-phorylation and compromises growth and survival of medulloblastoma cell lines. Oncogene. 2007;26(16):2308-2317.
45. Hartmann W, Koch A, Brune H, et al. Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells. Am J Pathol. 2005;166(4):1153-1162.
46. Patti R, Reddy CD, Geoerger B, et al. Autocrine secreted insulin-like growth factor-I stimulates MAP kinase-dependent mitogenic effects in human primitive neuroectodermal tumor/medulloblastoma. Int J Oncol. 2000;16(3):577-584.
47. Hahn H, Wojnowski L, Specht K, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem. 2000;275(37):28341-28344.
48. De Bont JM, van Doorn J, Reddingius RE, et al. Various components of the insulin-like growth factor system in tumor tissue, cerebrospi-nal flu id an d periph eral blood of pediatric medu lloblastoma and ependymoma patients. Int J Cancer. 2008;123(3):594-600.
49. Buhren J, Christoph AH, Buslei R, et al. Expression of the neurotrophin receptor p75NTR in medulloblastomas is correlated with distinct histological and clinical features: evidence for a medulloblastoma subtype derived from the external granule cell layer. J Neuropathol Exp Neurol. 2000;59(3):229-240.
50. Gazit R, Krizhanovsky V, Ben-Arie N. Math1 controls cerebellar granule cell differentiation by regulating multiple components of the Notch signaling pathway. Development. 2004;131(4):903-913.
51. Kruttgen A, Schneider I, Weis J. The dark side of the NGF family: neurotrophins in neoplasias. Brain Pathol. 2006;16(4):304-310.
52. Lee JE. NeuroD and neurogenesis. Dev Neurosci. 1997;19(1):27-32.
53. de Haas T, Oussoren E, Grajkowska W, et al. OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. J Neuropathol Exp Neurol. 2006;65(2):176-186.
54. Di C, Liao S, Adamson DC, et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retin-oic acid. Cancer Res. 2005;65(3):919-924.
55. Biegel JA, Rorke LB, Packer RJ, et al. Isochromosome 17q in primitive neuroectodermal tumors of the central nervous system. Genes Chromosomes Cancer. 1989;1(2):139-147.
56. Pan E, Pellarin M, Holmes E, et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res. 2005;11(13):4733-4740.
57. Biegel JA, Janss AJ, Raffel C, et al. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system. Clin Cancer Res. 1997;3(3):473-478.
58. Burnett ME, White EC, Sih S, et al. Chromosome arm 17p deletion analysis reveals molecular genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumors of the central nervous system. Cancer Genet Cytogenet. 1997;97(1):25-31.
59. Mendrzyk F, Korshunov A, Toedt G, et al. Isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats. Genes Chromosomes Cancer. 2006;45(4):401-410.
60. Briggs KJ, Corcoran-Schwartz IM, Zhang W, et al. Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma. Genes Dev. 2008;22(6):770-785.
61. Bulavin DV, Demidov ON, Saito S, et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet. 2002;31(2):210-215.
62. Hui AB, Takano H, Lo KW, et al. Identification of a novel homozygous deletion region at 6q23.1 in medulloblastomas using high-resolution array comparative genomic hybridization analysis. Clin Cancer Res. 2005;11(13):4707-4716.
63. Mendrzyk F, Radlwimmer B, Joos S, et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol. 2005;23(34):8853-8862.
64. McCabe MG, Ichimura K, Liu L, et al. High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol. 2006;65(6):549-561.
65. Lo KC, Rossi MR, Burkhardt T, et al. Overlay analysis of the oligonucleotide array gene expression profiles and copy number abnormalities as determined by array comparative genomic hybridization in medulloblastomas. Genes Chromosomes Cancer. 2007;46(1):53-66.
66. Yin XL, Pang JC, Ng HK. Identification of a region of homozygous deletion on 8p22-23.1 in medulloblastoma. Oncogene. 2002;21(9):1461-1468.
67. Lo KC, Rossi MR, Eberhart CG, et al. Genome wide copy number abnormalities in pediatric medulloblastomas as assessed by array comparative genome hybridization. Brain Pathol. 2007;17(3):282-296.
68. Rossi MR, Conroy J, McQuaid D, et al. Array CGH analysis of pediatric medulloblastomas. Genes Chromosomes Cancer. 2006;45(3):290-303.
69. Yin XL, Pang JC, Liu YH, et al. Analysis of loss of heterozygosity on chromosomes 10q, 11, and 16 in medulloblastomas. J Neurosurg. 2001;94(5):799-805.
70. Ehrbrecht A, Mu ller U, Wolter M, et al. Comprehen sive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J Pathol. 2006;208(4):554-563.
71. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415-428.
72. Lusher ME, Lindsey JC, Latif F, et al. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer Res. 2002;62(20):5906-5911.
73. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene. 2004;23(16):2950-2966.
74. Grotzer MA, Eggert A, Zuzak TJ, et al. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene. 2000;19(40):4604-4610.
75. Pfister S, Schlaeger C, Mendrzyk F, et al. Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma. Nucleic Acids Res. 2007;35(7):e51.
76. Uziel T, Zindy F, Xie S, et al. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev. 2005;19(22):2656-2667.
77. Peyrl A, Krapfenbauer K, Slavc I, et al. Protein profiles of medulloblastoma cell lines DAOY and D283: identification of tumor-related proteins and principles. Proteomics. 2003;3(9):1781-1800.
78. Horn B, Heideman R, Geyer R, et al. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol. 1999;21(3):203-211.
79. Merchant TE, Jenkins JJ, Burger PC, et al. Influence of tumor grade on time to progression after irradiation for localized ependymoma in children. Int J Radiat Oncol Biol Phys. 2002;53(1):52-57.
80. Grundy RG, Wilne SA, Weston CL, et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol. 2007;8(8):696-705.
81. Kato H, Uchimura I, Morohoshi M, et al. Multiple endocrine neoplasia type 1 associated with spinal ependymoma. Intern Med. 1996;35(4):285-289.
82. Lamszus K, Lachenmayer L, Heinemann U, et al. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. Int J Cancer. 2001;91(6):803-808.
83. Taylor MD, Poppleton H, Fuller C, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell. 2005; 8(4):323-335.
84. Conover JC, Doetsch F, Garcia-Verdugo JM, et al. Disruption of Eph/ephrin signaling affects migration and proliferation in the adult subventricular zone. Nat Neurosci. 2000;3(11):1091-1097.
85. Hitoshi S, Alexson T, Tropepe V, et al. Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes Dev. 2002;16(7):846-858.
86. Mullins KJ, Rubio A, Myers SP, et al. Malignant ependymomas in a patient with Turcot's syndrome: case report and management guidelines. Surg Neurol. 1998;49(3):290-294.
87. Suarez-Merino B, Hubank M, Revesz T, et al. Microarray analysis of pediatric ependymoma identifies a cluster of 112 can didate genes including four transcripts at 22q12.1-q13.3. Neuro-Oncology. 2005; 7(1):20-31.
88. Modena P, Lualdi E, Facchinetti F, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol. 2006;24(33):5223-5233.
89. Metzger AK, Sheffield VC, Duyk G, et al. Identification of a germlin e mu tati on in the p53 gene in a patien t with an intracran ial ependymoma. Proc Natl Acad Sci U S A. 1991;88(17):7825-7829.
90. Zamecnik J, Snuderl M, Eckschlager T, et al. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohis-tochemical, and flow cytometric factors. Mod Pathol. 2003;16(10): 980-991.
91. Michalides RJ. Cell cycle regulators: mechanisms and th eir role in aetiology, prognosis, and treatment of cancer. J Clin Pathol. 1999; 52(8):555-568.
92. Korshunov A, Golanov A, Timirgaz V. p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance: an analysis of 103 cases. Acta Neuropathol (Berl). 2001;102(3):271-277.
93. Sowar K, Straessle J, Donson AM, et al. Predicting which children are at risk for ependymoma relapse. J Neurooncol. 2006;78(1):41-46.
94. Lukashova-v Zangen I, Kneitz S, Monoranu CM, et al. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol. 2007;113(3):325-337.
95. Preusser M, Wolfsberger S, Czech T, et al. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol. 2005;124(4):543-549.
96. Wolfsberger S, Fischer I, Hoftberger R, et al. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am J Surg Pathol. 2004;28(7):914-920.
97. Hirose Y, Aldape K, Bollen A, et al. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol. 2001;158(3):1137-1143.
98. Mendrzyk F, Korshunov A, Benner A, et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res. 2006;12(7 pt 1):2070-2079.
99. Dyer S, Prebble E, Davison V, et al. Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol. 2002;161(6):2133-2141.
100. Jeuken JW, Sprenger SH, Gilhuis J, et al. Correlation between localization, age, and chromosomal imbalances in ependymal tumours as detected by CGH. J Pathol. 2002;197(2):238-244.
101. Hulsebos TJ, Oskam NT, Bijleveld EH, et al. Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter-22q11.2. Br J Cancer. 1999;81(7):1150-1154.
102. Rousseau-Merck M, Versteege I, Zattara-Cannoni H, et al. Fluorescence in situ hybridization determination of 22q12-q13 deletion in two intracerebral ependymomas. Cancer Genet Cytogenet. 2000;121(2):223-227.
103. Sevenet N, Sheridan E, Amram D, et al. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet. 1999;65(5):1342-1348.
104. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350-1354.
105. Vorechovsky I, Tingby O, Hartman M, et al. Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene. 1997;15(3):361-366.
106. Wolter M, Reifenberger J, Sommer C, et al. Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 1997;57(13):2581-2585.
107. Pietsch T, Waha A, Koch A, et al. Medulloblastomas of the desmo-plastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res. 1997;57(11):2085-2088.
108. Raffel C, Jenkins RB, Frederick L, et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res. 1997;57(5):842-845.
109. Zurawel RH, Allen C, Wechsler-Reya R, et al. Evidence that haploin-sufficiency of Ptch leads to medulloblastoma in mice. Genes Chromosomes Cancer. 2000;28(1):77-81.
110. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet. 2002;31(3):306-310.
111. Koch A, Waha A, Hartmann W, et al. No evidence for mutations or altered expression of the Su ppressor of Fused gene (SUFU ) in primitive neuroectodermal tumours. Neuropathol Appl Neurobiol. 2004;30(5):532-539.
112. Reifenberger J, Wolter M, Weber RG, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 1998;58(9):1798-1803.
113. Zurawel RH, Allen C, Chiappa S, et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer. 2000;27(1):44-51.
114. Di Marcotullio L, Ferretti E, De Smaele E, et al. REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma. Proc Natl Acad Sci U S A. 2004;101(29):10833-10838.
115. Dahmen RP, Koch A, Denkhaus D, et al. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res. 2001;61 (19):7039-7043.
116. Yokota N, Nishizawa S, Ohta S, et al. Role of Wnt pathway in medulloblastoma oncogenesis. Int J Cancer. 2002;101(2):198-201.
117. Koch A, Hrychyk A, Hartmann W, et al. Mutations of the Wnt antagonist AXI N2 (conductin) result in TCF-dependent transcription in medulloblastomas. Int J Cancer. 2007;121(2):284-291.
118. Koch A, Waha A, Tonn JC, et al. Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer. 2001;93(3):445-449.
119. Huang H, Mahler-Araujo BM, Sankila A, et al. APC mutations in sporadic medulloblastomas. Am J Pathol. 2000;156(2):433-437.
120. Zurawel RH, Chiappa SA, Allen C, et al. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res. 1998;58(5):896-899.
121. Ellison DW, Onilude OE, Lindsey JC, et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol. 2005;23(31):7951-7957.
122. Bodey B, Bodey V, Siegel SE, et al. Survivin expression in childhood medulloblastomas: a possible diagnostic and prognostic marker. In Vivo. 2004;18(6):713-718.
123. Haberler C, Slavc I, Czech T, et al. Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome. Eur J Cancer. 2006;42(17):2996-3003.
124. Yokota N, Mainprize TG, Taylor MD, et al. Identification of differentially expressed and developmentally regulated genes in medullo-blastoma using suppression subtraction hybridization. Oncogene. 2004;23(19):3444-3453.
125. Thomson SA, Kennerly E, Olby N, et al. Microarray analysis of differentially expressed genes of primary tumors in the canine central nervous system. Vet Pathol. 2005;42(5):550-558.
126. Gilbertson RJ, Perry RH, Kelly PJ, et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 1997;57(15):3272-3280.
127. Bal MM, Das Radotra B, Srinivasan R, et al. Does c-erbB-2 expression have a role in medulloblastoma prognosis? Indian J Pathol Microbiol. 2006;49(4):535-539.
128. Lee CJ, Chan WI, Scotting PJ. CIC, a gene involved in cerebellar development and ErbB signaling, is significantly expressed in medulloblastomas. J Neurooncol. 2005;73(2):101-108.
129. Stearns D, Chaudhry A, Abel TW, et al. c-Myc overexpression causes anaplasia in medulloblastoma. Cancer Res. 2006;66(2):673-681.
130. Aldosari N, Bigner SH, Burger PC, et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med. 2002;126(5):540-544.
131. Bruggers CS, Tai KF, Mu rdock T, et al. E xpression of th e c-Myc protein in childhood medulloblastoma. J Pediatr Hematol Oncol. 1998;20(1):18-25.
132. Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroec-todermal tumor/medulloblastoma. Clin Cancer Res. 2001;7(8):2425-2433.
133. Herms J, Neidt I, Luscher B, et al. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer. 2000; 89(5):395-402.
134. Sommer A, Waha A, Tonn J, et al. Analysis of the Max-binding protein MNT in human medulloblastomas. Int J Cancer. 1999;82(6):810-816.
135. Cvekl A, Jr., Zavadil J, Birshtein BK, et al. Analysis of transcripts from 17p13. 3 in medu lloblastoma suggests ROX/MN T as a potential tumour suppressor gene. Eur J Cancer. 2004;40(16):2525-2532.
136. Fruhwald MC, O'Dorisio MS, Rush LJ, et al. Gene amplification in PNETs/medulloblastomas: mapping of a novel amplified gene within the MYCN amplicon. J Med Genet. 2000;37(7):501-509.
137. Pession A, Tonelli R. The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. Curr Cancer Drug Targets. 2005;5(4):273-283.
138. Tomlinson FH, Jenkins RB, Scheithauer BW, et al. Aggressive medullo-blastoma with high-level N-myc amplification. Mayo Clin Proc. 1994;69(4):359-365.
139. Huang A, Ho CS, Ponzielli R, et al. Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells. Cancer Res. 2005;65(13):5607-5619.
140. Del Valle L, Enam S, Lassak A, et al. Insu lin -like growth factor I receptor activity in human medulloblastomas. Clin Cancer Res. 2002;8(6):1822-1830.
141. Schuller U, Koch A, Hartmann W, et al. Subtype-specific expression and genetic alterations of the chemokinereceptor gene CXCR4 in medulloblastomas. Int J Cancer. 2005;117(1):82-89.
142. Gilbertson RJ, Clifford SC. PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet. 2003;35(3):197-198.
143. Boon K, Eberhart CG, Riggins GJ. Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res. 2005;65(3):703-707.
144. Michiels EM, Oussoren E, Van Groenigen M, et al. Genes differentially expressed in medulloblastoma and fetal brain. Physiol Genomics. 1999;1(2):83-91.
145. Salsano E, Pollo B, Eoli M, et al. Expression of MATH1, a marker of cerebellar granule cell progenitors, identifies different medulloblastoma sub-types. Neurosci Lett. 2004;370(2-3):180-185.
146. Ohta T, Watanabe T, Katayama Y, et al. TrkA expression is associated with an elevated level of apoptosis in classic medulloblastomas. Neuropathology. 2006;26(3):170-177.
147. Grotzer MA, Janss AJ, Fung K, et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol. 2000;18(5):1027-1035.
148. Segal RA, Goumnerova LC, Kwon YK, et al. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medullo-blastoma. Proc Natl Acad Sci U S A. 1994;91(26):12867-12871.
149. Korshunov A, Golanov A, Timirgaz V. Immunohistochemical markers for prognosis of ependymal neoplasms. J Neurooncol. 2002;58(3):255-270.
150. Sinnappah-Kang ND, Mrak RE, Paulsen DB, et al. Heparanase expression and TrkC/p75NTR ratios in human medulloblastoma. Clin Exp Metastasis. 2006;23(1):55-63.
151. Sinnappah-Kang ND, Kaiser AJ, Blust BE, et al. Heparanase, TrkC and p75NTR: their functional involvement in human medulloblastoma cell invasion. Int J Oncol. 2005;27(3):617-626.
152. Salsano E, Croci L, Maderna E, et al. Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1. Neuro-Oncology. 2007;9(3):298-307.
153. Rostomily RC, Bermingham-McDonogh O, Berger MS, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 1997;57(16):3526-3531.
154. Katsetos CD, Herman MM, Krishna L, et al. Calbindin-D28k in subsets of medulloblastomas and in the human medulloblastoma cell line D283 Med. Arch Pathol Lab Med. 1995;119(8):734-743.
155. Adesina AM, Nalbantoglu J, Cavenee WK. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res. 1994;54(21):5649-5651.
156. Saylors RL 3rd, Sidransky D, Friedman HS, et al. Infrequent p53 gene mutations in medulloblastomas. Cancer Res. 1991;51(17):4721-4723.
157. Raffel C, Thomas GA, Tishler DM, et al. Absence of p53 mutations in childhood central nervous system primitive neuroectodermal tumors. Neurosurgery. 1993;33(2):301-306.
158. Nozaki M, Tada M, Matsumoto R, et al. Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: reappraisal by yeast functional assay. Acta Neuropathol. 1998;95(3):291-296.
159. Kozmik Z, Sure U, Ruedi D, et al. Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci U S A. 1995;92(12):5709-5713.
160. Giordana MT, Duo D, Gasverde S, et al. MDM2 overexpression is associated with short survival in adults with medulloblastoma. Neuro-Oncology. 2002;4(2):115-122.
161. Lindsey JC, Lusher ME, Anderton JA, et al. Identification of tumour-specific epigenetic events in medulloblastoma development by hyper-methylation profiling. Carcinogenesis. 2004;25(5):661-668.
162. Rood BR, Zhang H, Weitman DM, et al. Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma. Cancer Res. 2002;62(13):3794-3797.
163. De Bortoli M, Castellino RC, Lu XY, et al. Medulloblastoma outcome is adversely associated with overexpression of EEF1D, RPL30, and RPS20 on the long arm of chromosome 8. BMC Cancer. 2006; 6:223.
164. de Bont JM, den Boer ML, Kros JM, et al. Identification of novel bi omarkers in pediatric pri mitive neu roectodermal tu mors an d ependymomas by proteome-wide analysis. J Neuropathol Exp Neurol. 2007;66(6):505-516.
165. Yoshimoto M, Bayani J, Nuin PA, et al. Metaphase and array comparative genomic hybridization: unique copy number changes and gene amplification of medulloblastomas in South America. Cancer Genet Cytogenet. 2006;170(1):40-47.
166. Fan X, Wang Y, Kratz J, et al. hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am J Pathol. 2003;162(6):1763-1769.
167. Waha A, Koch A, Hartmann W, et al. SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblasto-mas. Oncogene. 2007;26(38):5662-5668.
168. Ebinger M, Senf L, Wachowski O, et al. Promoter methylation pattern of caspase-8, P16INK4A, MGMT, TIMP-3, and E-cadherin in medulloblastoma. Pathol Oncol Res. 2004;10(1):17-21.
169. Zuzak TJ, Steinhoff DF, Sutton LN, et al. Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. Eur J Cancer. 2002;38(1):83-91.
170. Pingoud-Meier C, Lang D, Janss AJ, et al. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res. 2003;9(17):6401-6409.
171. Gonzalez-Gomez P, Bello MJ, Inda MM, et al. Deletion and aberrant CpG island methylation of caspase 8 gene in medulloblastoma. Oncol Rep. 2004;12(3):663-666.
172. Muhlisch J, Bajanowski T, Rickert CH, et al. Frequent but borderline methylation of p16 (INK4a) and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. J Neurooncol 2007.
173. Fruhwald MC, O'Dorisio MS, Dai Z, et al. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas-implications for tumor biology and potential clinical utility. Oncogene. 2001;20(36):5033-5042.
174. Uziel T, Zindy F, Sherr CJ, et al. The CDK inhibitor p18Ink4c is a tumor suppressor in medulloblastoma. Cell Cycle. 2006;5(4):363-365.
175. Lindsey JC, Lusher ME, Anderton JA, et al. Epigenetic deregulation of multiple S100 gene family members by differential hypomethylation and hypermethylation events in medulloblastoma. Br J Cancer. 2007;97(2):267-274.
176. Lindsey JC, Lusher ME, Strathdee G, et al. Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. Int J Cancer. 2006;118(2):346-352.
177. Gonzalez-Gomez P, Bello MJ, Alonso ME, et al. CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br J Cancer. 2003;88(1):109-114.
178. Vibhakar R, Foltz G, Yoon JG, et al. Dickkopf-1 is an epigenetically silenced candidate tu mor su ppressor gen e in medu lloblastoma. Neuro-Oncology. 2007;9(2):135-144.
179. Gilbertson RJ, Bentley L, Hernan R, et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res. 2002;8(10):3054-3064.
180. Ogino S, Kubo S, Abdul-Karim FW, et al. Comparative immuno-histochemical study of insulin-like growth factor II and insulin-like growth factor receptor type 1 in pediatric brain tumors. Pediatr Dev Pathol. 2001;4(1):23-31.
181. Korshunov A, Neben K, Wrobel G, et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol. 2003;163(5):1721-1727.
182. Rubio MP, Correa KM, Ramesh V, et al. Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res. 1994;54(1):45-47.
183. Birch BD, Johnson JP, Parsa A, et al. Frequent type 2 neurofibromatosis gene transcript mutations in sporadic intramedullary spinal cord ependymomas. Neurosurgery. 1996;39(1):135-140.
184. Ebert C, von Haken M, Meyer-Puttlitz B, et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol. 1999;155(2):627-632.
185. Michalowski MB, de Fraipont F, Michelland S, et al. Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet. 2006;166(1):74-81.
186. Alonso ME, Bello MJ, Gonzalez-Gomez P, et al. Aberrant CpG island methylation of multiple genes in ependymal tumors. J Neurooncol. 2004;67(1-2):159-165.
187. Urioste M, Martinez-Ramirez A, Cigudosa JC, et al. Complex cytogen etic abnormalities including telomeric associations and MEN1 mutation in a pediatric ependymoma. Cancer Genet Cytogenet. 2002;138(2):107-110.
188. Rushing EJ, Yashima K, Brown DF, et al. Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas. J Neuropathol Exp Neurol. 1997;56(10):1142-1146.
189. Tong CY, Ng HK, Pang JC, et al. Molecular genetic analysis of non-astrocytic gliomas. Histopathology. 1999;34(4):331-341.
190. Gaspar N, Grill J, Geoerger B, et al. p53 Pathway dysfunction in primary childhood ependymomas. Pediatr Blood Cancer. 2006;46(5):604-613.
191. von Haken MS, White EC, Daneshvar-Shyesther L, et al. Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas. Genes Chromosomes Cancer. 1996;17(1):37-44.
192. Fink KL, Rushing EJ, Schold SC Jr, et al. Infrequency of p53 gene mutations in ependymomas. J Neurooncol. 1996;27(2):111-115.
193. Suzuki SO, Iwaki T. Amplification and overexpression of mdm2 gene in ependymomas. Mod Pathol. 2000;13(5):548-553.
194. Loiseau H, Arsaut J, Demotes-Mainard J. p73 gene transcripts in human brain tumors: overexpression and altered splicing in ependymomas. Neurosci Lett. 1999;263(2-3):173-176.
195. Kamiya M, Nakazato Y. The expression of p73, p21 and MDM2 proteins in gliomas. J Neurooncol. 2002;59(2):143-149.
196. Hamilton DW, Lusher ME, Lindsey JC, et al. Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. Cancer Lett. 2005;227(1):75-81.
197. Alonso ME, Bello MJ, Gonzalez-Gomez P, et al. Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet. 2003;144(2):134-142.
198. Rousseau E, Ruchoux MM, Scaravilli F, et al. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol Appl Neurobiol. 2003;29(6):574-583.
199. Waha A, Koch A, Hartmann W, et al. Analysis of HIC-1 methylation and transcription in human ependymomas. Int J Cancer. 2004;110(4):542-549.
200. Bhattacharjee MB, Armstrong DD, Vogel H, et al. Cytogenetic analysis of 120 primary pediatric brain tumors and literature review. Cancer Genet Cytogenet. 1997;97(1):39-53.
201. Neumann E, Kalousek DK, Norman MG, et al. Cytogenetic analysis of 109 pediatric central nervous system tumors. Cancer Genet Cytogenet. 1993;71(1):40-49.
202. Bayani J, Zielenska M, Marrano P, et al. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg. 2000;93(3):437-448.
203. Stratton MR, Darling J, Lantos PL, et al. Cytogenetic abnormalities in human ependymomas. Int J Cancer. 1989;44(4):579-581.
204. Bigner SH, McLendon RE, Fuchs H, et al. Chromosomal characteristics of childhood brain tumors. Cancer Genet Cytogenet. 1997;97(2):125-134.
205. Biegel JA, Rorke LB, Janss AJ, et al. Isochromosome 17q demonstrated by interphase fluorescence in situ hybridization in primitive neuroec-todermal tumors of the central nervous system. Genes Chromosomes Cancer. 1995;14(2):85-96.
206. Vagner-Capodano AM, Zattara-Cannoni H, Gambarelli D, et al. Cytogenetic study of 33 ependymomas. Cancer Genet Cytogenet. 1999;115(2):96-99.
207. Cohen N, Betts DR, Tavori U, et al. Karyotypic evolution pathways in medulloblastoma/primitive neuroectodermal tumor determined with a combination of spectral karyotyping, G-banding, and fluorescence in situ hybridization. Cancer Genet Cytogenet. 2004;149(1):44-52.
208. Vagner-Capodano AM, Zattara-Cannoni H, Gambarelli D, et al. Detection of i(17q) chromosome by fluorescent in situ hybridization (FISH) with interphase nuclei in medulloblastoma. Cancer G enet Cytogenet. 1994;78(1):1-6.
209. Ransom DT, Ritland SR, Kimmel DW, et al. Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chromosomes Cancer. 1992;5(4):348-356.
210. Chadduck WM, Boop FA, Sawyer JR. Cytogenetic studies of pediatric brain and spinal cord tumors. Pediatr Neurosurg. 1991;17(2): 57-65.
211. Vagner-Capodano AM, Gentet JC, Gambarelli D, et al. Cytogenetic studies in 45 pediatric brain tumors. Pediatr Hematol Oncol. 1992;9(3):223-235.
212. Weremowicz S, Kupsky WJ, Morton CC, et al. Cytogenetic evidence for a chromosome 22 tumor suppressor gene in ependymoma. Cancer Genet Cytogenet. 1992;61(2):193-196.
213. Rogatto SR, Casartelli C, Rainho CA, et al. Chromosomes in the genesis and progression of ependymomas. Cancer Genet Cytogenet. 1993;69(2):146-152.
214. Agamanolis DP, Malone JM. Chromosomal abnormalities in 47 pediatric brain tumors. Cancer Genet Cytogenet. 1995;81(2):125-134.
215. Yamada K, Kasama M, Kondo T, et al. Chromosome studies in 70 brain tumors with special attention to sex chromosome loss and single autosomal trisomy. Cancer Genet Cytogenet. 1994;73(1):46-52.
216. Mazewski C, S ou kup S, Ballard E, et al. Karyotype stu dies in 18 ependymomas with literature review of 107 cases. Cancer G enet Cytogenet. 1999;113(1):1-8.
217. Sawyer JR, Miller JP, Ellison DA. Clonal telomeric fusions and chromosome instability in a subcutaneous sacrococcygeal myxopapillary ependymoma. Cancer Genet Cytogenet. 1998;100(2):169-175.
218. Sainati L, Bolcato S, Montaldi A, et al. Cytogenetics of pediatric central nervous system tumors. Cancer Genet Cytogenet. 1996;91(1):13-27.
219. Pearson AD, Reid MM, Davison EV, et al. Cytogenetic investigations of solid tumours of children. Arch Dis Child. 1988;63(9):1012-1015.
220. Dal Cin P, San dberg AA. Cytogenetic findings in a su pratentorial ependymoma. Cancer Genet Cytogenet. 1988; 30(2):289-293.
221. Karnes PS, Tran TN, Cui MY, et al. Cytogenetic analysis of 39 pediatric central nervous system tumors. Cancer Genet Cytogenet. 1992;59(1):12-19.
222. Thiel G, Losanowa T, Kintzel D, et al. Karyotypes in 90 human gliomas. Cancer Genet Cytogenet. 1992;58(2):109-120.
223. Roberts P, Chumas PD, Picton S, et al. A review of the cytogenetics of 58 pediatric brain tumors. Cancer Genet Cytogenet. 2001;131(1):1-12.
224. Avet-Loiseau H, Venuat AM, Terrier-Lacombe MJ, et al. Comparative genomic hybridization detects many recurrent imbalances in central nervous system primitive neuroectodermal tumours in children. Br J Cancer. 1999;79(11-12):1843-1847.
225. Eberhart CG, Kratz JE, Schuster A, et al. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol. 2002;12(1):36-44.
226. Nishizaki T, Harada K, Kubota H, et al. Genetic alterations in pediatric medulloblastomas detected by comparative genomic hybridization. Pediatr Neurosurg. 1999;31(1):27-32.
227. Gilh uis H J, Anderl KL, Boerman RH, et al. Comparative genomic hybridization of medu lloblastomas and clinical relevance: eleven new cases and a review of the literature. Clin Neurol Neurosurg. 2000;102(4):203-209.
228. Inda MM, Perot C, Guillaud-Bataille M, et al. Genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumours of the central nervous system. Histopathology. 2005;47(6):631-637.
229. Reardon DA, Michalkiewicz E, Boyett JM, et al. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res. 1997;57(18):4042-4047.
230. Shlomit R, Ayala AG, Michal D, et al. Gains and losses of DNA seq u en ces in ch ildh ood brain tumors analyzed by comparative genomic hybridization. Cancer Genet Cytogenet. 2000;121(1):67-72.
231. Michiels EM, Weiss MM, Hoovers JM, et al. Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization. J Pediatr Hematol Oncol. 2002;24(3):205-210.
232. Russo C, Pellarin M, Tingby O, et al. Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer. 1999;86(2):331-339.
233. Brown HG, Kepner JL, Perlman EJ, et al. "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group study. J Neuropathol Exp Neurol. 2000;59(10):857-865.
234. Jay V, Squire J, Bayani J, et al. Oncogene amplification in medulloblastoma: analysis of a case by comparative genomic hybridization and fluorescence in situ hybridization. Pathology. 1999;31(4):337-344.
235. Tong CY, Hui AB, Yin XL, et al. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J Neurosurg. 2004;100(2 suppl Pediatrics):187-193.
236. Nicholson J, Wickramasinghe C, Ross F, et al. Imbalances of chromosome 17 in medulloblastomas determined by comparative genomic hybridisation and fluorescence in situ hybridisation. Mol Pathol. 2000;53(6):313-319.
237. Gilhuis HJ, van der Laak J, Wesseling P, et al. Inverse correlation between genetic aberrations and malignancy grade in ependymal tumors: a paradox? J Neurooncol. 2004;66(1-2):111-116.
238. Reardon DA, Entrekin RE, Sublett J, et al. Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes Chromosomes Cancer. 1999;24(3):230-237.
239. Ward S, Harding B, Wilkins P, et al. Gain of 1q and loss of 22 are the most common changes detected by comparative genomic hybridisation in paediatric ependymoma. Genes Chromosomes Cancer. 2001;32(1):59-66.
240. Grill J, Avet-Loiseau H, Lellouch-Tubiana A, et al. Comparative genomic hybridization detects specific cytogenetic abnormalities in pediatric ependymomas and choroid plexus papillomas. Cancer Genet Cytogenet. 2002;136(2):121-125.
241. Carter M, Nicholson J, Ross F, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer. 2002;86(6):929-939.
242. Scheil S, Bruderlein S, Eicker M, et al. Low frequency of chromosomal imbalances in anaplastic ependymomas as detected by comparative genomic hybridization. Brain Pathol. 2001;11(2):133-143.
243. Zheng PP, Pang JC, Hui AB, et al. Comparative genomic hybridization detects losses of chromosomes 22 and 16 as the most common recurrent genetic alterations in primary ependymomas. Cancer Genet Cytogenet. 2000;122(1):18-25.
244. Rickert CH, Korshunov A, Paulus W. Chromosomal imbalances in clear cell ependymomas. Mod Pathol. 2006;19(7):958-962.
245. Granzow M, Popp S, Weber S, et al. Isochromosome 1q as an early genetic event in a child with intracranial ependymoma characterized by molecular cytogenetics. Cancer Genet Cytogenet. 2001;130(1):79-83.
246. Schutz BR, Scheurlen W, Krauss J, et al. Mapping of chromosomal gains and losses in primitive neuroectodermal tumors by comparative genomic hybridization. Genes Chromosomes Cancer. 1996;16(3):196-203.